Kornimate/medical-research-clean huggingface dataset:
serum and peritoneal cea and ca 19-9 for gastric adenocarcinoma

Conditions: Gastric Adenocarcinoma

Summary: for preoperative staging and prediction of peritoneal dissemination of gastric adenocarcinoma, usage of serum and peritoneal levels of carcinoembryonic antigen (cea) and ca 19-9 may be helpful. additionally, the prognosis of the patients with gastric adenocarcinoma treated with gastrectrectomy may be associated with serum and peritoneal levels of tumor markers.

clinical usage of tumor markers on preoperative staging and prediction of peritoneal dissemination of gastric adenocarcinoma is a controversial issue. it has been thought that there is a positive correlation between serum and peritoneal levels of carcinoembryonic antigen (cea) and ca 19-9 and pathologic features of gastric tumors and peritoneal dissemination. in this study, it was aimed to evaluate the effect of serum and peritoneal cea and ca 19-9 to predict tnm stages and peritoneal washing cytology in patients with gastric adenocarcinoma after curative gastrectomy, and to determine predictive value of these measurements to the development of recurrence and death.

Eligibility criteria:
inclusion criteria: * endoscopically proven gastric adenocarcinoma * standard gastrectomy and a d2 lymph node dissection; * desire to attend the study protocol exclusion criteria: * metastatic or overt peritoneal disseminated cancer * undesired reaction to attend the study protocol

Keywords: gastric adenocarcinoma tumor markers peritoneal cytology
clinical study of first-line treatment of small cell lung cancer (sclc) with anlotinib hydrochloride

Conditions: Small Cell Lung Cancer

Summary: this study was designed to investigate the efficacy and side effects of combining erlotinib with classical ec/ep chemotherapy regimens.

lung cancer is a common malignant tumor that poses a serious threat to human health. small cell lung cancer accounts for about 20% of lung cancer. precision medicine has recently been perfectly interpreted in many tumor types, but the treatment of small cell lung cancer is still bleak. the ec/ep regimen is the most classic chemotherapy regimen for small cell lung cancer with good results but is prone to drug resistance. in 2018, with the development of immunotargeting therapy, small molecule multi-target anti-angi drugs, parp inhibitors, new chemotherapy drugs, etc., the treatment of small cell lung cancer has ushered in a new dawn. as a kind of highly selective multi-target anti-angiogenic tki drugs,anlotinib hydrochloride is a kind of 1.1 innovative drugs with independent intellectual property rights in china, mainly acting on vegfr, pdgfr, fgfr and c-kit. the latest alter1202 study confirms that anlotinib is significantly improved for psc and orr in sclc patients who have previously received at least 2-line chemotherapy. os data is not yet mature, but the benefits of the anlotinib group were observed. the adverse effects of anlotinib were consistent with expectations, no new adverse events were found, and safety was tolerated. nowadays, the effective combination of traditional chemical therapy with molecular targeting and immunotherapy is the future development direction of lung cancer treatment. therefore, this topic is designed to combine the efficacy of safety and safety with the treatment of anlotinib with the classic ec/ep chemotherapy regimen. expected to get longer pfs and os for patient benefit.

Eligibility criteria:
inclusion criteria: 1. patients 18-75 years of age. 2. a metastatic or recurrent advanced sclc confirmed by histology or cytology and did not receive any other treatment; 3. a measurable disease 4. an eastern cooperative oncology group ps of 0-1; 5. an estimated survival duration of \>6 months; exclusion criteria: 1. have used erlotinib or other anti-vascular targeted drugs (eg, endo, bevacizumab, etc.)2. patients who have been treated with chemotherapy or radiotherapy for previous tumors.3.have appeared or merged with other tumors within 5 years.4.patients with no measurable lesions; 5.any severe and uncontrolled disease.
immunogenicity and safety trial of adjuvanted and non-adjuvanted trivalent influenza vaccine in tropical africa

Conditions: Influenza

Summary: this study will provide the senegal ministry of health with data on the safety and immunogenicity of adjuvanted trivalent inactivated influenza vaccine (adjtiv) and full-dose seasonal non-adjuvanted trivalent inactivated influenza vaccine (tiv) in children. this data will inform future policy considerations for influenza vaccine. the study is not powered to detect significant differences between vaccines or groups, and no hypotheses are to be tested; therefore, immunogenicity and safety objectives are to be analyzed descriptively.

the is a phase 2b, single-center, randomized, observer-blind, parallel group, placebo-controlled trial of the immunogenicity and safety of adjtiv and seasonal tiv among healthy children aged 6 months through 71 months in the town of niakhar, senegal. a total of 300 healthy children will be randomized in a 2:2:1 ratio of adjtiv to tiv to placebo. each child will receive two doses of one of the three study vaccines, with each dose given 28 days apart. each child will be followed closely for safety after each dose for the period from one month post-dose two to 3 months post-dose two. for determination of immune response to vaccination or background influenza infection, 3 ml of blood will be obtained at three time points: pre-vaccination, 28 days post-dose one (prior to receipt of dose two), and at 28 days post-dose two. serum anti-influenza antibodies produced against virus strains contained in the vaccine will be detected using hemagglutination inhibition assay.

Eligibility criteria:
inclusion criteria: * a male or female child at least 6 months of age and under 6 years of age (has not yet reached 72 months of age) at the enrollment visit. * free of obvious health problems, as established by the medical history and screening evaluations, including physical examination. * subject's parent or legal guardian is willing to provide written informed consent prior to the subject's first study vaccination. exclusion criteria: * known hypersensitivity to any component in adjtiv or tiv (which include egg protein) or placebo. * receipt of any non-study vaccine within two weeks prior to enrollment or refusal to postpone receipt of such vaccines until after the day 56 visit. * previous receipt of any influenza vaccine. * hypersensitivity after previous administration of any vaccine. * acute illness accompanied by a body temperature of 37.5°c or greater (axillary measurement) within 14 days of enrollment visit. (enrollment and administration of adjtiv, tiv, or placebo should be postponed until at least 14 days after recovery. minor illnesses, such as mild upper respiratory infection, with an axillary temperature of \<37.5°c, are not reason for exclusion or postponing study vaccination.) * any condition that, in the opinion of the investigator, would pose a health risk to the participant if he/she participates in the study or would interfere with the evaluation of the study objectives.

Keywords: influenza influenza vaccine immunogenicity africa senegal
physiotherapy for persistent function by superficial neuromodulation

Conditions: Post-Acute COVID-19 Syndrome; Dysautonomia; Neuromodulation

Summary: objectives: to evaluate pressure pain thresholds, fatigue scales, quality of life and sleep quality, in women with persistent covid (pc), pre- and post-treatment using electrotherapy and in a placebo group of pc patients. relevance: this trial can be a tool for patients affected by cp who present pain and fatigue problems, insomnia or signs of imbalance of their autonomic nervous system. it aims to improve their rest and recovery for a better quality of life that allows them to recover their activities of daily living. we have designed the study with a commitment to placebo group treatment after completion, if positive results are obtained. a 6-month and 1-year follow-up will be scheduled. secondary objectives: to analyze the effects on quality of life, fatigue and sleep. to analyze the presence of cardiac variability and pre- and post-treatment cortisol values. patients and methods: 12 patients with cp will receive 15 sessions of electrotherapy. 12 will receive a placebo. mechanical sensitivity pre-post, by means of an algometer, cardiac variability, cortisol levels, and other variables, will be measured by means of questionnaires. mechanical sensitivity to pain will be measured using an algometer (baseline 12-0300 mmt). patients will be instructed to report when the sensation of pressure changes to pain. the pre-post electrotherapy treatment described above will be measured, the differences in mechanical sensitivity, pain threshold to pressure, the pittsburg questionnaires, sf-36, mfis and eqool-5. follow-up will be done at 6 months and at one year. the study design is a triple-blind randomized controlled clinical trial. patients who sign the consent form will be evaluated by an internist who will perform a physical examination at the clinic of the faculty of nursing and physiotherapy of the pontifical university of salamanca (upsa). the sample will be randomized. 12 patients will receive treatment and 12 patients will receive a placebo. with a commitment to treat these patients in the event that positive results are obtained after the end of the study. a biphasic microcurrent will be applied with a frequency between 1.14 hertz and 14.29 hertz and intensities between 0.1 and 0.9 ma. frequency: 2 times a week. a total of 15 sessions in 7.5 weeks. the session time with microcurrents will last 60 minutes. .


Eligibility criteria:
inclusion criteria: * women who have had symptoms of pc for more than one year. * signs of central sensitization. exclusion criteria: * previous treatment with surgery. * previous spinal trauma. * whiplash. * pregnancy situation. * previous musculoskeletal disease (rheumatoid arthritis, sympathetic-reflex dystrophy, fibromyalgia). * pacemaker. * electric drug pump. * skin sensitivity alterations. * analgesic or anxiolytic drug treatment during the study.
a study of icp-189 and icp-189 in combination with anti-pd-1 monoclonal antibody in patients with advanced solid tumors

Conditions: Patients With Advanced Solid Tumors

Summary: a dose finding study to evaluate the safety, tolerability and pharmacokinetics and preliminary anti-tumor activity of icp-189 tablets and icp-189 tablets in combination with anti-pd-1 monoclonal antibody in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. eastern cooperative oncology group (ecog) performance status of 0-1; 2. patients with histologically confirmed locally advanced unresectable or metastatic solid tumors; 3. at least one measurable lesion according to recist 1.1. exclusion criteria: 1. patients who have had other cancer(s) within 5 years prior to the first dose, except for locally curable cancers that have been apparently cured; 2. patients with unstable primary central nervous system (cns) tumors or cns metastases; 3. patients who have an active autoimmune disease or have had an autoimmune disease with risk of recurrence; 4. patients who have active or history of interstitial lung disease or non-infectious pneumonia; 5. patients who have a history of severe allergic reaction to any component of icp-189 tablets or anti-pd-1 antibody (\> grade 3 assessed by ctcae 5.0). other protocol-defined inclusion/exclusion criteria apply.
phase 2 dasatinib combo with smoothened (smo) antagonist (bms-833923)

Conditions: Leukemia

Summary: the purpose of the study is to compare response rates in newly diagnosed chronic phase (cp) cml subjects treated with dasatinib plus bms-833923 versus dasatinib alone.

1. design: study design and duration as current described are no longer applicable since enrollment was prematurely concluded due to a decision by the sponsor. subjects currently enrolled in the trial will continue to receive dasatinib alone at a starting dose of 100 mg qd for: 1. a maximum of 5 years after entry into the study 2. until progression by investigators determination/judgment 3. intolerance to dasatinib 4. the study is terminated due to safety concerns or 5. other administrative reasons as communicated by the sponsor 2. research hypothesis : the research hypothesis and primary objective of this study as originally designed are no longer applicable as subjects enrolment has been terminated due to administrative reasons by the sponsor. the objective of the altered design of this study is to describe the safety profile and tolerability of dasatinib

Eligibility criteria:
inclusion criteria: * subjects ≥ 18 years of age who have signed informed consent * philadelphia positive chronic myeloid leukemia (cml) in chronic phase * previously untreated chronic phase cml, except for anagrelide or hydroxyurea. * eastern co-operative group (ecog) performance status (ps) score 0 - 2 exclusion criteria: * known abl-kinase t315i or t315a mutation * serious or uncontrolled medical disorder (including infection or cardiovascular disease) or dementia or other serious psychiatric condition * prior chemotherapy. * women who are pregnant or breastfeeding or women of child bearing potential (wocbp) who are unwilling or unable to use an acceptable method to avoid pregnancy during the entire study period.

Keywords: myelogenous chronic bcr-abl positive
spinal needles in ultrasound-guided fine needle aspirations from thyroid nodules

Conditions: Thyroid Nodule

Summary: this is a multicentre, two-arm, randomised and controlled trial. adults with thyroid nodules suspected of malignancy are to be included consecutively. a total of 350 patients are randomly assigned 1:1 to have fna with a spinal (25g) or a conventional (25g) needle. the primary outcome is the rate of diagnostic cytological samples according to the bethesda system. secondary outcomes are diagnostic accuracy, patient's experienced pain and complication rates.


Eligibility criteria:
inclusion criteria: 1. ≥18 years of age. 2. patients referred for evaluation of a cold nodule on thyroid scintigraphy and with eu-tirads score of 3 or higher. * score 3 and \> 20 mm in size. * score 4 and \>15 mm in size. * score 5 and \>10 mm in size. 3. clinical suspicion of thyroid cancer: * pet-positive thyroid tumor. * thyroid tumor and palsy of the recurrent laryngeal nerve. * rapidly growing thyroid tumor. * hard and/or immobile thyroid tumor. * tumor in the thyroid with suspicious lymph nodes. exclusion criteria: * previous participation in the study. * language or other barriers not allowing adequate information.
dolorisk: research on risk factors and determinants for neuropathic pain

Conditions: Neuropathic Pain

Summary: patients with neuropathic pain of multiple etiologies and a control cohort of patients with the same neuropathic entities who did not develop neuropathic pain are examined clinically, phenotyped with qst and questionnaires. both groups are analyzed in order to find risk factors for painful neuropathy.

patients with probable (presence of a combination of symptoms and signs of neuropathy include any two or more of the following: neuropathic symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes) or confirmed (presence of an abnormality of nc or validated measure of small fiber neuropathy with class 1 evidence with corresponding symptoms) neuropathy are included. patients are then further divided into those with painful and painless neuropathy according to the neupsig algorithm. patients with probable or definite neuropathic pain are classified as painful neuropathy, those with unlikely neuropathic pain classified as painless neuropathy (with concomitant nociceptive pain of other origin, e.g. headache etc.). patients with possible neuropathic pain are excluded from analysis as are patients with skin lesions or dermatological disorders in the areas to be tested upon qst, with any painful or neurological comorbidity that could otherwise influence testing results such as vascular disease, radiculopathy, spinal canal stenosis etc. inclusion was restricted to patients with polyneuropathy to make the investigated patient sample as homogenous as possible. age, gender, bmi, ethnicity, years in education, family history of chronic pain, etiology of neuropathy, presence of early traumatic events and hospital admissions, smoking and alcohol habits, pain characteristics (von korff, bpsi, npsi), emotional well-being (promis depression/ anxiety), personality (tipi, ipip, pcs), severity of neuropathy are assessed and qst performed.

Eligibility criteria:
inclusion criteria: - diagnosis of polyneuropathy exclusion criteria: * patients with polyneuropathy and possible neuropathic pain * patients with skin lesions or dermatological disorders in the areas to be tested upon qst * patients with any painful or neurological comorbidity that could otherwise influence testing results such as vascular disease, radiculopathy, spinal canal stenosis etc.

Keywords: pain prevention painful neuropathy, painless neuropathy qst patient-reported outcomes pro
remote ischemic limb preconditioning in healthy volunteers

Conditions: Cerebrovascular Disease; Stroke

Summary: the investigators would like to determine if remote ischemic leg preconditioning in healthy volunteers improves cerebral vasomotor reactivity as measured by breath holding and transcranial doppler vasomotor reactivity.

this study is to determine if remote ischemic leg preconditioning improves short and long term cerebral vasomotor reactivity in healthy volunteers as measured by breath holding and transcranial doppler vasomotor reactivity. previous studies on brachial vasomotor reactivity have shown a beneficial effect of remote ischemic preconditioning. it remains uncertain if a similar beneficial effect can be reproduced with cerebral vasomotor testing. many biological mechanisms and effector pathways triggered by preconditioning have demonstrated endothelial protection and beneficial vascular effects.

Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * presence of chronic medical conditions such as diabetes, hypertension, cardiac disease etc. * any prescribed medication * pregnancy \[by history and last menstrual period\] * any leg injury that would, in the opinion of the investigator, affect preconditioning
a pilot study of fenofibrate and ursodeoxycholic acid in the treatment of newly diagnosed primary biliary cholangitis

Conditions: Primary Biliary Cholangitis (PBC)

Summary: this study is a prospective, single center, randomized controlled, exploratory clinical trial aimed at evaluating the efficacy and safety of fenofibrate in newly diagnosed pbc subjects.


Eligibility criteria:
inclusion criteria: * must have provided written informed consent * age 18-75 years; * bmi 17-28 kg/m2 * male or female with a diagnosis of pbc, by at least two of the following criteria: 1. history of ap above uln for at least six months; 2. positive ama titers (\&gt;1/40 on immunofluorescence or m2 positive by enzyme linked immunosorbent assay (elisa) or positive pbc-specific antinuclear antibodies; 3. documented liver biopsy result consistent with pbc. * not receiving udca treatment before enrollment, alp\&gt;uln exclusion criteria: * history or presence of other concomitant liver diseases. * alt or ast \&gt; 5×uln, tbil \&gt; 3×uln. * if female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating. * allergic to fenofibrate or ursodeoxycholic acid. * taking hepatotoxic drugs (e.g., dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for more than 2 weeks within 6 months, and long-term hormonal users. * recurrent variceal bleeding, poorly controlled hepatic encephalopathy or refractory ascites. * patients with a history of severe cardiac, cerebrovascular, renal, respiratory disease or functional failure, and psychiatric disorders (including those due to alcohol and drug abuse). * creatinine \>1.5×uln and creatinine clearance \<60 ml/min. * currently using statins (such as pravastatin, fluvastatin, and simvastatin), other fibrates (such as gemfibrozil and bezafibrate), and drugs structurally similar to fenofibrate (like ketoprofen). * planned to receive an organ transplant or an organ transplant recipient. * needing liver transplantation within 1 year according to the mayo rick score. * any other condition(s) that would compromise the safety of the subject or compromise
antibiotic nephrotoxicity in adult patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: adult patients with cystic fibrosis (cf) are treated with high dose antibiotics to reduce the long term damage to their lungs from infection. this would typically be with a two week course of intravenous antibiotics each time they have a chest infection (typically three to four times a year). the most effective and commonly used antibiotic in most cases is tobramycin. if this cannot be used because of previous side effects, allergy or a resistant infection then colomycin or amikacin are usually used. each of these antibiotics are known to be toxic to both the kidneys and ear. as patients are living longer (into their forties), the total amount of these antibiotics they are receiving over their lifetime is increasing. this is now leading to increased complications such as kidney damage and hearing loss. because of this, the investigators need to look at methods to accurately quantify damage and reduce potential kidney and hearing damage. the investigators intend to quantify kidney damage by measuring new protein markers within the urine and blood that signify kidney damage before more conventional and currently available methods are able to.in those patients treated with intravenous tobramycin the investigators will also look at an alternative method used to calculate the most appropriate dose of antibiotic for each participant. this dosing method is called 'area under the curve or auc' dose monitoring. this method currently in clinical use in other countries is thought to more accurately reflect the most appropriate dose for each participant and thus reduce the chance of kidney and hearing problems. this 'auc' method requires two rather than one dose level to be checked each time a dose calculation is made. participants receiving tobramycin will be randomised to receive dosing by this method or the investigators' currently used method of 'trough' monitoring.


Eligibility criteria:
inclusion criteria: * diagnosis of cf\* * able to give written informed consent * pulmonary exacerbation requiring iv tobramycin, amikacin or colistin based on the decision of the treating physician exclusion criteria: * known allergy or adverse reaction to proposed antibiotic (tobramycin, amikacin or colistin) * pregnancy (if found to be pregnant during the study the participant will be immediately withdrawn) * continuation of nebulised aminoglycoside or colistin during iv treatment * use or intended use of nsaids
pronostic impact of flow fraction reserve on intermediate stenoses

Conditions: Coronary Stenosis

Summary: the intermediate coronary stenoses defined by a degree of stenosis from 40 to 70 % are frequent. the flow fraction reserve (ffr), realized during coronarography, is an hemodynamic evaluation by the functional impact measuring the loss of load in upstream / approval of the stenosis inthe basal state and in situation of hyperemia led by adenosine. further to the study fame, the threshold of definition of the significant character of one stenosis was fixed for a value of ffr = 0,80. however, the impact forecasts intermediate values badly known rest. we hypothetized that coronary stenosis associated with borderline values of ffr 0.81-0.85 were associated with a higher rate of clinical events than those with a ffr \>0.85


Eligibility criteria:
inclusion criteria: * patient with ffr\> 0,80 between september 2012 till december 2016 exclusion criteria: * refusal of participation